Literature DB >> 21367607

Boron neutron capture therapy for clear cell sarcoma (CCS): biodistribution study of p-borono-L-phenylalanine in CCS-bearing animal models.

T Andoh1, T Fujimoto, T Sudo, I Fujita, M Imabori, H Moritake, T Sugimoto, Y Sakuma, T Takeuchi, S Kawabata, M Kirihata, T Akisue, K Yayama, M Kurosaka, S Miyatake, Y Fukumori, H Ichikawa.   

Abstract

Clear cell sarcoma (CCS) is a rare melanocytic malignant tumor with a poor prognosis. Our previous study demonstrated that in vitro cultured CCS cells have the ability to highly uptake l-BPA and thus boron neutron capture therapy could be a new option for CCS treatment. This paper proved that a remarkably high accumulation of (10)B (45-74 ppm) in tumor was obtained even in a CCS-bearing animal with a well-controlled biodistribution followed by intravenous administration of L-BPA-fructose complex (500 mg BPA/kg). Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21367607     DOI: 10.1016/j.apradiso.2011.02.005

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  2 in total

1.  Development and Elucidation of a Novel Fluorescent Boron-Sensor for the Analysis of Boronic Acid-Containing Compounds.

Authors:  Yoshihide Hattori; Takuya Ogaki; Miki Ishimura; Yoichiro Ohta; Mitsunori Kirihata
Journal:  Sensors (Basel)       Date:  2017-10-24       Impact factor: 3.576

2.  Understanding the potentiality of accelerator based-boron neutron capture therapy for osteosarcoma: dosimetry assessment based on the reported clinical experience.

Authors:  Silva Bortolussi; Ian Postuma; Nicoletta Protti; Lucas Provenzano; Cinzia Ferrari; Laura Cansolino; Paolo Dionigi; Olimpio Galasso; Giorgio Gasparini; Saverio Altieri; Shin-Ichi Miyatake; Sara J González
Journal:  Radiat Oncol       Date:  2017-08-15       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.